YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Leading industry experts will come together for multi-day conference to discuss how advancements in AI-driven automation, agentic AI, and data analytics will accelerate clinical trials BOSTON, October 08, 2026--(BUSINESS WIRE)--eClinical S…
Asian equities traded in the US as American depositary receipts were falling sharply Wednesday morni PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Uniting industry leaders to build the digital standards and infrastructure needed for the future of drug development DOVER, Del., Oct. 6, 2026 /PRNewswire/ -- The Digital CMC Consortium today launched as a new industry collaboration unitin…
Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base. For investors watching Takeda stock today, the core i…
A model for private sector–nonprofit collaboration in tackling life-threatening health risks WASHINGTON & TOKYO, October 01, 2026--(BUSINESS WIRE)--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutic…
Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in…
Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate t…
Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Takeda (TAK) said Wednesday that its experimental pill zasocitinib showed superior results compared PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week…
Keros Therapeutics KROS announced that it has dosed the first patient in the phase II study evaluating its lead pipeline candidate, rinvatercept, in patients with Duchenne muscular dystrophy (DMD). The open-label, multi-cohort basket study…
Ginkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris' federated infrastructure enables participating pharmaceutical companies to use those models and further fine-tune them on the…
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs…
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer TAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-…
Iambic Therapeutics, Inc., an AI drug discovery company backed by Nvidia Corp.(NASDAQ:NVDA) and the Qatar Investment Authority, filed for an initial public offering, according to an S-1 filing with the SEC on Monday. Plans to List on Nasda…
Bristol Myers BMY recently announced positive two-year results from the late-stage POETYK PsA-2 study on Sotyktu (deucravacitinib), including its open-label extension (OLE). The two-year data provide additional support for Sotyktu's commer…
2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh) Commitment of USD 22.2 Million Increases Takeda's Total Glo…
Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date fal…
Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same…
The myelodysplastic syndrome market is poised for steady growth, driven by the increasing burden of MDS among the aging population, rising disease awareness, and the growing adoption of innovative therapies across lower- and higher-risk pa…
Hummingbird Bioscience Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience…
Asian equities traded in the US as American depositary receipts started the trading week heading sha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amgen…
Here are three stocks with buy rank and strong value characteristics for investors to consider today, September 14: Signet Jewelers Limited SIG: This global retail giant of diamond jewellery carries a Zacks Rank #1, and has witnessed the Z…
Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 14: Ternium S.A. TX: This steel products company has witnessed the Zacks Consensus Estimate for its current year earnings incr…
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generatio…
Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform™, demonstrating how AI is reshaping patient recruitment – and where it goes from here MALMO, Sweden & WILMINGTON, Del., September 09, 2026--(BUSINESS W…
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previo…
Onco360 Oncology Pharmacy LOUISVILLE, Ky., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MI…
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million…
DelveInsight Business Research LLP Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist…
U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additio…
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at val…
Company Logo Complement Inhibitors MarketComplement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule…
Quick Read NVAX jumped 7% on unverified Matrix-M oncology speculation, even as the real story had already quietly resumed: high-teens royalties on Sanofi's Nuvaxovid global net sales restarted for 2026 and 2027. IBB gained just 0.2% while…
Co-authored IND submission preparation study results demonstrate ~97% reduction in time to first draft and 60% overall timeline compression SAN FRANCISCO, September 01, 2026--(BUSINESS WIRE)--Weave Bio, the leader in AI-native regulatory a…